We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Clinical Benefit of Cognitive Behaviour Therapy (CBT) for Insomnia in Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00134108
Recruitment Status : Unknown
Verified January 2003 by NHS Greater Clyde and Glasgow.
Recruitment status was:  Active, not recruiting
First Posted : August 24, 2005
Last Update Posted : October 26, 2005
Cancer Research UK
Information provided by:
NHS Greater Clyde and Glasgow

Brief Summary:
The purpose of this study is to conduct a formal controlled evaluation of the potential benefits of CBT for insomnia in cancer patients.

Condition or disease Intervention/treatment
Insomnia Cancer Behavioral: Cognitive Behaviour Therapy

Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomised Controlled Clinical Effectiveness Trial of Cognitive Behaviour Therapy (CBT) Versus Treatment as Usual (TAU) for Insomnia in Cancer Patients
Study Start Date : January 2003
Estimated Study Completion Date : December 2005

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Meets clinical criteria for insomnia.
  • Diagnosis of breast, prostate, colorectal or gynaecological cancer.
  • In follow-up phase with no further anti-cancer therapy planned.

Exclusion Criteria:

  • Anti-cancer chemotherapy or radiotherapy within 4 weeks of trial entry.
  • Evidence of sleep apnoea or other sleep disorder.
  • Evidence of untreated major depressive disorder.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00134108

United Kingdom
North Glasgow and Grampian Trusts
Glasgow and Aberdeen, United Kingdom
Sponsors and Collaborators
NHS Greater Glasgow and Clyde
Cancer Research UK
Principal Investigator: Colin Espie, PhD University of Glasgow

ClinicalTrials.gov Identifier: NCT00134108     History of Changes
Other Study ID Numbers: C8265/A3036
First Posted: August 24, 2005    Key Record Dates
Last Update Posted: October 26, 2005
Last Verified: January 2003

Additional relevant MeSH terms:
Sleep Initiation and Maintenance Disorders
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Nervous System Diseases
Mental Disorders